MINNEAPOLIS--(BUSINESS WIRE)--Medtronic (NYSE:MDT) today announced the start of its MOMIJI (Miracle-ICD Outcome Measured In Japanese Indication) clinical trial; the first large-scale, post-market study conducted in Japan sponsored by a medical device company. The MOMIJI trial, which is a prospective, multi-center study enrolling up to 250 patients at approximately 25 centers in Japan, will evaluate the effectiveness of cardiac resynchronization therapy-defibrillator (CRT-D) in Japanese patients as compared to patients studied in the MIRACLE-ICD trial. The MIRACLE-ICD study was a randomized, double-blinded, parallel-controlled clinical trial to evaluate the efficacy of CRT-D in heart failure patients in the United States.
